Literature DB >> 28750932

Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension.

Mareike Lankeit1, Valentin Krieg2, Lukas Hobohm3, Sebastian Kölmel2, Christoph Liebetrau4, Stavros Konstantinides2, Christian W Hamm4, Eckhard Mayer5, Christoph B Wiedenroth5, Stefan Guth5.   

Abstract

BACKGROUND: Management and outcome of patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) who underwent pulmonary endarterectomy (PEA) at a large German referral center were investigated.
METHODS: In Germany, 394 PEAs were performed in 2014 and 2015 with an in-hospital mortality rate of 5.8%. Of these, 253 patients (64.2%) were treated at the Kerckhoff Clinic, Bad Nauheim, and 237 (93.7%; median age, 62 years [interquartile range [IQR], 52-72 years]; 46.0% female) were included in the present analysis.
RESULTS: On referral, 52 patients (22.0%) were treated with pulmonary arterial hypertension-specific drugs and 95 (40.4%) were treated with non-vitamin K-dependent oral anticoagulants, and 14 (5.9%) had mean pulmonary artery pressure <25 mm Hg and were classified as having chronic thromboembolic pulmonary vascular disease. PEA was feasible in 236 (99.6%) patients with median duration of surgery of 397 minutes (IQR, 363-431 minutes). Periprocedural (0%) and in-hospital (2.5%) mortality rates were very low. Forty-two patients (17.7%) had intraoperative complications, and 60 (25.3%) had post-operative complications. The duration of surgery was the only predictor of in-hospital mortality (≥500 minutes; odds ratio [OR], 32.0; 95% confidence interval [CI], 5.5-187.6) and the only independent predictor of intraoperative (≥440 minutes; OR, 10.8; 95% CI, 4.4-26.5) and post-operative (≥390 minutes; OR, 2.4; 95%CI, 1.1-5.7) complications. Only intraoperative complications independently predicted a longer duration of surgery (≥397 minutes; OR, 5.0; 95% CI, 2.2-11.2).
CONCLUSIONS: In an experienced center with multidisciplinary diagnostic and therapeutic approaches, PEA is safe. Prognosis was mainly determined by occurrence of intraoperative complications and duration of surgery rather than patients' pre-operative status.
Copyright © 2017 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  balloon pulmonary angioplasty; chronic thromboembolic pulmonary hypertension; non–vitamin K–dependent oral anticoagulants; prognosis; pulmonary endarterectomy

Year:  2017        PMID: 28750932     DOI: 10.1016/j.healun.2017.06.011

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  8 in total

1.  Correlation of native T1 mapping with right ventricular function and pulmonary haemodynamics in patients with chronic thromboembolic pulmonary hypertension before and after balloon pulmonary angioplasty.

Authors:  F C Roller; S Kriechbaum; A Breithecker; C Liebetrau; M Haas; C Schneider; A Rolf; S Guth; E Mayer; C Hamm; G A Krombach; C B Wiedenroth
Journal:  Eur Radiol       Date:  2018-08-29       Impact factor: 5.315

2.  Pulmonary endarterectomy reoperation: frequency, risk factors and outcomes.

Authors:  Stefan Guth; Christoph B Wiedenroth; Eckhard Mayer
Journal:  Ann Cardiothorac Surg       Date:  2022-03

3.  Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension: a systematic review.

Authors:  John D L Brookes; Crystal Li; Sally T W Chung; Elizabeth M Brookes; Michael L Williams; Nicholas McNamara; Sofia Martin-Suarez; Antonio Loforte
Journal:  Ann Cardiothorac Surg       Date:  2022-03

Review 4.  Pulmonary endarterectomy: technique and pitfalls.

Authors:  Stefan Guth; Eckhard Mayer; Diethard Prüfer; Christoph B Wiedenroth
Journal:  Ann Cardiothorac Surg       Date:  2022-03

5.  Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry.

Authors:  Stefan Guth; Andrea M D'Armini; Marion Delcroix; Kazuhiko Nakayama; Elie Fadel; Stephen P Hoole; David P Jenkins; David G Kiely; Nick H Kim; Irene M Lang; Michael M Madani; Hiromi Matsubara; Aiko Ogawa; Jaquelina S Ota-Arakaki; Rozenn Quarck; Roela Sadushi-Kolici; Gérald Simonneau; Christoph B Wiedenroth; Bedrettin Yildizeli; Eckhard Mayer; Joanna Pepke-Zaba
Journal:  ERJ Open Res       Date:  2021-08-16

6.  Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension.

Authors:  Eleni Diamanti; Vasiliki Karava; Patrick Yerly; John David Aubert
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.241

7.  Direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension and the presence of recent thrombus during pulmonary endarterectomy.

Authors:  Ina Jeong; Mona Alotaibi; Timothy M Fernandes; Suhyun Kim; Kim M Kerr; Jenny Yang; Victor Pretorius; Michael Madani; Nick H Kim
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

8.  Non-Invasive Approach for Evaluation of Pulmonary Hypertension Using Extracellular Vesicle-Associated Small Non-Coding RNA.

Authors:  Christoph Lipps; Philipp Northe; Ricardo Figueiredo; Manfred Rohde; Alexandra Brahmer; Eva-Maria Krämer-Albers; Christoph Liebetrau; Christoph B Wiedenroth; Eckhard Mayer; Steffen D Kriechbaum; Oliver Dörr; Holger Nef; Christian W Hamm; Till Keller; Christian Troidl
Journal:  Biomolecules       Date:  2019-10-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.